Rodman & Renshaw initiated coverage of Ascentage Pharma (AAPG) with a Buy rating and $48 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AAPG:
- Ascentage Pharma Wins FDA IND Clearance for BTK Degrader APG-3288 to Enter Global Phase I Trial
- Ascentage Pharma’s APG-3288 receives IND clearance from FDA
- Ascentage Pharma to Present at J.P. Morgan Healthcare Conference
- Ascentage Pharma initiated with a Buy at Lucid Capital
- Ascentage Pharma Showcases Promising Data for Olverembatinib at ASH 2025